We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Protein Patterns in Blood Can Predict IBD As Early As 16 Years Before Diagnosis

By LabMedica International staff writers
Posted on 27 Nov 2024
Print article
Image: Specific protein patterns in the blood can predict IBD up to 16 years before onset (Photo courtesy of 123RF)
Image: Specific protein patterns in the blood can predict IBD up to 16 years before onset (Photo courtesy of 123RF)

Inflammatory bowel disease (IBD) is particularly challenging because it can progress for years without showing symptoms, leading to damage in the gastrointestinal tract before treatment begins. Now, scientists have discovered specific protein patterns in blood that can predict IBD up to 16 years before it is diagnosed. This is especially true for Crohn’s disease, which can be detected with remarkable accuracy.

Researchers at Örebro University (Örebro, Sweden) analyzed nearly 800 blood samples and identified distinct protein patterns that differentiate healthy individuals from those who later develop Crohn’s disease or ulcerative colitis. Their findings revealed that a particular combination of 29 proteins could predict Crohn’s disease with high accuracy. In contrast, predicting ulcerative colitis proved to be more difficult. The study showed that changes in protein patterns could be detected in individuals with Crohn’s disease as early as 16 years before diagnosis. According to the research published in Gastroenterology, the results emphasize that proteins related to intestinal barrier function and the immune system play a critical role in understanding the development of Crohn’s disease.

“We’ve taken an important step towards us being able to predict and prevent these diseases at a very early stage in the future,” said Jonas Halfvarson, professor of gastroenterology at Örebro University, and lead researcher of the study. “By discovering these markers long before symptoms make themselves known, we can potentially intervene earlier and hopefully improve quality of life for those individuals that risk developing IBD.”

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.